Administration of Intracoronary Eptifibatide During ST-Elevation Myocardial Infarction

Pinto, Duane S.; Kirtane, Ajay J.; Ruocco, Nicholas A.; Deibele, Albert J.; Shui, Amy; Buros, Jacki; Murphy, Sabina A.; Gibson, C. Michael

doi:10.1016/j.amjcard.2005.07.056

Cited by 18 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TFG TIMI flow grade. deaths, reinfarctions, or TIMI major bleeding events, and just two episodes of TIMI minor bleeding 22) , in the ICE trial there were no angiographic, electrophysiological, or other adverse findings attributable to the IC administration of eptifibatide. There were no perforations, pericardial effusions, or clinical evidence for intracardiac hematomas or mechanical complications of infarction observed with IC eptifibatide and no significant difference in the groups with procedurerelated myonecrosis.…”

Section: Fig 2 Post-pci Timi Flow Gradementioning

confidence: 99%

Comparison between the Outcomes of Intracoronary and Intravenous Administration of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Acute ST-Elevation Myocardial Infarction

Esfandi

Fotouhi

Allami

et al. 2016

JAT

View full text Add to dashboard Cite

show abstract

Section: Fig 2 Post-pci Timi Flow Gradementioning

confidence: 99%

Comparison between the Outcomes of Intracoronary and Intravenous Administration of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Acute ST-Elevation Myocardial Infarction

Esfandi

Fotouhi

Allami

et al. 2016

JAT

View full text Add to dashboard Cite

show abstract

“…There was an increase in the final TMPG 3 (54%) with eptifibatide [63]. The administration of IC tirofiban [750 lg (10 lg/kg)], a small molecule platelet IIb/IIIa inhibitor, has also been associated with resolution of intracoronary thrombus in the setting of an acute STEMI [64][65][66][67].…”

Section: Ic Glycoprotein Iibiiia Inhibitorsmentioning

confidence: 99%

Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction

Kunadian

Zorkun

Williams

et al. 2008

J Thromb Thrombolysis

Self Cite

View full text Add to dashboard Cite

Although percutaneous coronary intervention restores optimal epicardial blood flow in most cases, abnormal myocardial perfusion may still persist. This might be as a result of macro and microembolization, neutrophil plugging, vasoconstriction, myocyte contracture, local intracellular and interstitial edema, intramural haemorrhage, and endothelial blistering. Local delivery of intracoronary pharmacotherapy via the coronary arteries may increase local drug concentration several fold, and may improve drug efficacy. Several pharmacological agents such as adenosine, calcium channel blockers, alpha blockers, beta2 receptor activators, vasodilators, antithrombotics, and antiplatelet agents have been used to treat coronary microvascular dysfunction. This article reviews the results of trials of intracoronary pharmacotherapy to date.

show abstract

“…Through this catheter, eptifibatide was administered at doses similar to those used by Pinto et al [17], as follows:…”

Section: Methodsmentioning

confidence: 99%

Microvascular Effect of Intracoronary Eptifibatide in Acute Myocardial Infarction

Iancu

Ober²,

Bondor

et al. 2012

Cardiology

View full text Add to dashboard Cite

Objectives: In this prospective, randomized trial in patients with acute myocardial infarction (AMI) admitted for primary percutaneous coronary intervention (PPCI), loaded with 600 mg clopidogrel, we hypothesized that eptifibatide administered downstream of the coronary occlusion leads to a lower degree of microvascular obstruction compared with no additional eptifibatide. Methods: Fifty patients with AMI, loaded with 600 mg of clopidogrel at the first hospital contact, with occlusion of the left anterior descending artery (LAD), were randomized to an eptifibatide group (EG) or a control group (CG). In both groups, stenting was performed after thrombus aspiration. Microvascular reperfusion was assessed by angiography, electrocardiography, and transthoracic Doppler ultrasonography of the LAD. Results: TIMI myocardial perfusion grade 2–3 was not different between the EG (72%) and the CG (84%) (p = 0.31). ST segment resolution >70% was similarly detected in both groups (32 vs. 40%; p = 0.56). The mean diastolic deceleration time did not differ significantly between the CG (856.36 ± 397.88 ms) and the EG (935.72 ± 252.22 ms) (p = 0.41). Multivariate logistic regression revealed no significant influence of the treatment with eptifibatide on ST segment resolution (OR 0.47; 95% CI 0.11–2.10, p = 0.32), TIMI myocardial perfusion (OR 0.52; 95% CI 0.10–2.59, p = 0.42), and diastolic deceleration time (OR 0.21; 95% CI 0.03–1.51, p = 0.12). Conclusions: In AMI patients loaded with 600 mg of clopidogrel undergoing PPCI, intracoronary administration of eptifibatide does not clearly improve microvascular obstruction.

show abstract

Administration of Intracoronary Eptifibatide During ST-Elevation Myocardial Infarction

Cited by 18 publications

References 15 publications

Comparison between the Outcomes of Intracoronary and Intravenous Administration of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Acute ST-Elevation Myocardial Infarction

Comparison between the Outcomes of Intracoronary and Intravenous Administration of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Acute ST-Elevation Myocardial Infarction

Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction

Microvascular Effect of Intracoronary Eptifibatide in Acute Myocardial Infarction

Contact Info

Product

Resources

About